Top

Published in:

Open Access 01-09-2021 | Radiotherapy | Original Article

Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose

Authors: L. Wilke, C. Moustakis, O. Blanck, D. Albers, C. Albrecht, Y. Avcu, R. Boucenna, K. Buchauer, T. Etzelstorfer, C. Henkenberens, D. Jeller, K. Jurianz, C. Kornhuber, M. Kretschmer, S. Lotze, K. Meier, P. Pemler, A. Riegler, A. Röser, D. Schmidhalter, K. H. Spruijt, G. Surber, V. Vallet, R. Wiehle, J. Willner, P. Winkler, A. Wittig, M. Guckenberger, S. Tanadini-Lang

Published in: Strahlentherapie und Onkologie | Issue 9/2021

Abstract

Purpose

Dose, fractionation, normalization and the dose profile inside the target volume vary substantially in pulmonary stereotactic body radiotherapy (SBRT) between different institutions and SBRT technologies. Published planning studies have shown large variations of the mean dose in planning target volume (PTV) and gross tumor volume (GTV) or internal target volume (ITV) when dose prescription is performed to the PTV covering isodose. This planning study investigated whether dose prescription to the mean dose of the ITV improves consistency in pulmonary SBRT dose distributions.

Materials and methods

This was a multi-institutional planning study by the German Society of Radiation Oncology (DEGRO) working group Radiosurgery and Stereotactic Radiotherapy. CT images and structures of ITV, PTV and all relevant organs at risk (OAR) for two patients with early stage non-small cell lung cancer (NSCLC) were distributed to all participating institutions. Each institute created a treatment plan with the technique commonly used in the institute for lung SBRT. The specified dose fractionation was 3 × 21.5 Gy normalized to the mean ITV dose. Additional dose objectives for target volumes and OAR were provided.

Results

In all, 52 plans from 25 institutions were included in this analysis: 8 robotic radiosurgery (RRS), 34 intensity-modulated (MOD), and 10 3D-conformal (3D) radiation therapy plans. The distribution of the mean dose in the PTV did not differ significantly between the two patients (median 56.9 Gy vs 56.6 Gy). There was only a small difference between the techniques, with RRS having the lowest mean PTV dose with a median of 55.9 Gy followed by MOD plans with 56.7 Gy and 3D plans with 57.4 Gy having the highest. For the different organs at risk no significant difference between the techniques could be found.

Conclusions

This planning study pointed out that multiparameter dose prescription including normalization on the mean ITV dose in combination with detailed objectives for the PTV and ITV achieve consistent dose distributions for peripheral lung tumors in combination with an ITV concept between different delivery techniques and across institutions.

Available only for authorised users

Raz DJ, Zell JA, Ou SI et al (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132(1):193–199CrossRef

Rocco G, Morabito A, Leone A et al (2016) Management of non-small cell lung cancer in the era of personalized medicine. Int J Biochem Cell Biol 78:173–179CrossRef

Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630–637CrossRef

Guckenberger M, Allgäuer M, Appold S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non–small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8(8):1050–1058CrossRef

Maquilan G, Timmerman R (2016) Stereotactic body radiation therapy for early-stage lung cancer. Cancer J 22(4):274–279. https://doi.org/10.1097/ppo.0000000000000204CrossRefPubMed

Collen C, Christian N, Schallier D et al (2014) Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 25(10):1954–1959CrossRef

Guckenberger M, Klement RJ, Allgäuer M et al (2016) Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol 118(3):485–491CrossRef

Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non–small-cell lung cancer. J Clin Oncol 32(34):3824–3830CrossRef

Rieber J, Streblow J, Uhlmann L et al (2016) Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group “stereotactic radiotherapy”. J Lung Cancer 97:51–58CrossRef

10.

Rusthoven KE, Kavanagh BD, Burri SH et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579–1584CrossRef

11.

Tanadini-Lang S, Rieber J, Filippi AR et al (2017) Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol 123(2):182–188CrossRef

12.

Klement RJ, Allgäuer M, Andratschke N et al (2016) Bayesian cure rate modeling of local tumor control: evaluation in stereotactic body radiation therapy for pulmonary metastases. Int J Radiat Oncol Biol Phys 94(4):841–849CrossRef

13.

Giglioli FR, Strigari L, Ragona R et al (2016) Lung stereotactic ablative body radiotherapy: a large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. Phys Med 32(4):600–606CrossRef

14.

Landberg T, Chavaudra J, Dobbs J et al (2016) Report 50. J Int Comm Radiat Units Meas. https://doi.org/10.1093/jicru/os26.1.Report50CrossRef

15.

Landberg T, Chavaudra J, Dobbs J et al (2016) Report 62. J Int Comm Radiat Units Meas. https://doi.org/10.1093/jicru/os32.1.Report62CrossRef

16.

Units ICoR, Measurements (2010) ICRU report 83 prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 10(1):1–3

17.

Seuntjens S, Lartigau E, Cora S et al (2014) ICRU report 91. Prescribing, recording, and reporting of stereotactic treatments with small photon beams. J ICRU 14(2):101–109CrossRef

18.

Moustakis C, Blanck O, Tazehmahalleh FE et al (2017) Planning benchmark study for SBRT of early stage NSCLC. Strahlenther Onkol 193(10):780–790CrossRef

19.

Guckenberger M, Andratschke N, Dieckmann K et al (2017) ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 124(1):11–17CrossRef

20.

de Jong EEC, Guckenberger M, Andratschke N et al (2020) Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother Oncol 142:217–223. https://doi.org/10.1016/j.radonc.2019.11.001CrossRefPubMed

21.

Baumann R, Chan MK, Pyschny F et al (2018) Clinical results of mean GTV dose optimized robotic-guided stereotactic body radiation therapy for lung tumors. Front Oncol 8:171CrossRef

22.

Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy. Strahlenther Onkol 190(1):26–33CrossRef

23.

Klement RJ, Sonke J‑J, Allgäuer M et al (2020) Correlating dose variables with local tumor control in stereotactic body radiotherapy for early stage non-small cell lung cancer: A modelling study on 1500 individual treatments. Int J Radiat Oncol Biol Phys 107(3):579–586. https://doi.org/10.1016/j.ijrobp.2020.03.005CrossRefPubMed

24.

Feuvret L, Noël G, Mazeron J‑J et al (2006) Conformity index: a review. Int J Radiat Oncol Biol Phys 64(2):333–342CrossRef

25.

Paddick I (2000) A simple scoring ratio to index the conformity of radiosurgical treatment plans. J Neurosurg 93(Suppl 3):219–222CrossRef

26.

Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101CrossRef

27.

Guckenberger M, Baus WW, Blanck O et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 196(5):417–420. https://doi.org/10.1007/s00066-020-01603-1CrossRefPubMedPubMedCentral

28.

Guckenberger M (2015) Oligoprogression. Strahlenther Onkol 191(5):453–455CrossRef

29.

SABR UK Consortium (2019) Stereotactic Ablative Body Radiation therapy (SABR): A resource. The Royal College of Radiologists,

30.

Ong CL, Verbakel WF, Cuijpers JP et al (2010) Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol 97(3):437–442CrossRef

31.

Weyh A, Konski A, Nalichowski A et al (2013) Lung SBRT: dosimetric and delivery comparison of RapidArc, TomoTherapy, and IMRT. J Appl Clin Med Phys 14(4):3–13CrossRef

32.

Seppala J, Suilamo S, Kulmala J et al (2012) A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours. Radiat Oncol 7(1):79CrossRef

33.

Wilke L, Andratschke N, Blanck O et al (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlenther Onkol 195(3):193–198CrossRef

34.

Rieber J, Abbassi-Senger N, Adebahr S et al (2017) Influence of institutional experience and technological advances on outcome of stereotactic body radiation therapy for oligometastatic lung disease. Int J Radiat Oncol Biol Phys 98(3):511–520CrossRef

35.

Giglioli FR, Garibaldi C, Blanck O et al (2020) Dosimetric multicenter planning comparison studies for stereotactic body radiation therapy: methodology and future perspectives. Int J Radiat Oncol Biol Phys 106(2):403–412. https://doi.org/10.1016/j.ijrobp.2019.10.041CrossRefPubMed

36.

Esposito M, Masi L, Zani M et al (2019) SBRT planning for spinal metastasis: indications from a large multicentric study. Strahlenther Onkol 195(3):226–235. https://doi.org/10.1007/s00066-018-1383-2CrossRefPubMed

37.

Villaggi E, Hernandez V, Fusella M et al (2019) Plan quality improvement by DVH sharing and planner’s experience: Results of a SBRT multicentric planning study on prostate. Phys Med 62:73–82. https://doi.org/10.1016/j.ejmp.2019.05.003CrossRefPubMed

38.

Leung RWK, Chan MKH, Chiang CL et al (2020) On the pitfalls of PTV in lung SBRT using type‑B dose engine: an analysis of PTV and worst case scenario concepts for treatment plan optimization. Radiat Oncol 15(1):130. https://doi.org/10.1186/s13014-020-01573-9CrossRefPubMedPubMedCentral

39.

Ehrbar S, Jöhl A, Tartas A et al (2017) ITV, mid-ventilation, gating or couch tracking—A comparison of respiratory motion-management techniques based on 4D dose calculations. Radiother Oncol 124(1):80–88. https://doi.org/10.1016/j.radonc.2017.05.016CrossRefPubMed

40.

Ehrbar S, Perrin R, Peroni M et al (2016) Respiratory motion-management in stereotactic body radiation therapy for lung cancer—A dosimetric comparison in an anthropomorphic lung phantom (LuCa). Radiother Oncol 121(2):328–334. https://doi.org/10.1016/j.radonc.2016.10.011CrossRefPubMed

41.

Guckenberger M, Wilbert J, Krieger T et al (2007) Four-dimensional treatment planning for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 69(1):276–285. https://doi.org/10.1016/j.ijrobp.2007.04.074CrossRefPubMed

42.

Hansen CR, Crijns W, Hussein M et al (2020) Radiotherapy Treatment plannINg study Guidelines (RATING): a framework for setting up and reporting on scientific treatment planning studies. Radiother Oncol 153:67–78. https://doi.org/10.1016/j.radonc.2020.09.033CrossRefPubMed

Title: Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose
Authors: L. Wilke
C. Moustakis
O. Blanck
D. Albers
C. Albrecht
Y. Avcu
R. Boucenna
K. Buchauer
T. Etzelstorfer
C. Henkenberens
D. Jeller
K. Jurianz
C. Kornhuber
M. Kretschmer
S. Lotze
K. Meier
P. Pemler
A. Riegler
A. Röser
D. Schmidhalter
K. H. Spruijt
G. Surber
V. Vallet
R. Wiehle
J. Willner
P. Winkler
A. Wittig
M. Guckenberger
S. Tanadini-Lang
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keyword: Radiotherapy
Published in: Strahlentherapie und Onkologie / Issue 9/2021
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-021-01799-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose

Abstract

Purpose

Materials and methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2021

Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial

Inoperable CASTLE of the thyroid gland treated with radical radiotherapy with complete remission

Prädiktion der pathologischen Komplettremission beim Ösophaguskarzinom nach neoadjuvanter Radiochemotherapie mittels FDG-PET/CT und diffusionsgewichteter MRT

Value of PET imaging for radiation therapy

Konditionierung mit Ganzkörperbestrahlung oder Chemotherapie bei ALL im Kindesalter

Strahlentherapie mit 24-Gy-Einzeldosis und 3-Fraktionen-SBRT zur Behandlung von oligometastasierten Malignomen?